ESR1 and breast carcinoma: Regarding node positive ER/PgR-positive, HER2-negative breast cancer, ASCO warns that “more data are required to determine whether PAM50-ROR can be used with confidence in guiding the use of adjuvant systemic therapy.” Further, no data support the use of PAM50-ROR in HER2-positive breast cancer or in triple negative breast cancer (23).